Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial-Reference-Cited by-同舟云学术

Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

Published:2018-09-11 Issue:12 Volume:20 Page:1701-1709
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Bouabdallaoui Nadia¹,Claggett Brian²,Zile Michael R.³,McMurray John J.V.⁴,O'Meara Eileen¹,Packer Milton⁵,Prescott Margarett F.⁶,Swedberg Karl⁷,Solomon Scott D.²,Rouleau Jean L.¹,

Affiliation:

1. Montreal Heart Institute and University of Montreal Montreal, Quebec Canada

2. Brigham and Women's Hospital Boston MA USA

3. Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center Charleston SC USA

4. BHF Cardiovascular Research CentreUniversity of Glasgow Glasgow UK

5. Baylor University Medical Center Dallas TX USA

6. Novartis Pharmaceuticals Corporation East Hanover NJ USA

7. University of Gothenburg Gothenburg Sweden

Funder

Novartis

Publisher

Wiley